FDA Restricts IRB Following Two Failed Inspections

The FDA has halted approval of new trials and enrollment in ongoing studies reviewed by the investigational review board (IRB) BioMed after two negative assessments of the board’s work. BioMed was cited for numerous regulatory violations, including its lack of members with the necessary professional experience, according to a March 29 warning letter.
Drug Industry Daily